Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.40 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19788684 | 0.87 | ACHE (0.47) | AOC3ACHESMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL5966724 | 0.81 | ACHE (0.48) | AOC3ACHESMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL21310342 | 0.80 | MAPT (0.45) | AOC3SMN1; SMN2TSHRALDH1A1CSF1R | |
| SCHEMBL13338024 | 0.79 | CYP19A1 (0.44) | AOC3ACHESMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL450600 | 0.78 | TRPM8 (0.57) | AOC3SMN1; SMN2TSHRALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL30391062 | 0.77 | TRPM8 (0.56) | AOC3SMN1; SMN2TSHRALDH1A1MAPT | |
| SCHEMBL15264049 | 0.77 | ALDH1A1 (0.46) | ACHESMN1; SMN2TSHRALDH1A1MAPT | |
| SCHEMBL19700140 | 0.77 | AOC3 (0.44) | AOC3SMN1; SMN2TSHRALDH1A1CSF1R | |
| SCHEMBL10581787 | 0.76 | MAPT (0.52) | ACHETSHRALDH1A1MAPTKMT2A | |
| SCHEMBL11108577 | 0.75 | ACHE (0.49) | ACHEALDH1A1MAPTKMT2ACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2266977-B1 | 2,4-di[(hetero)arylamino]-pyrimidine derivatives as zap-70 and/or syk inhibitors | NOVARTIS AG (CH) | 2014-05-14 | — | — | EP | disclosed |
| US-8283356-B2 | 2,4- Di(hetero)-arylamino-pyrimidine derivatives as ZAP-70 and/or SYK inhibitors | NOVARTIS AG (CH) | 2012-10-09 | — | — | US | disclosed |
| EP-2266977-A1 | 2,4-di[(hetero)arylamino]-pyrimidine derivatives as zap-70 and/or syk inhibitors | Novartis AG (CH) | 2010-12-29 | — | — | EP | disclosed |
| EP-2266977-A1 | 2,4-di[(hetero)arylamino]-pyrimidine derivatives as zap-70 and/or syk inhibitors | Novartis AG (CH) | 2010-12-29 | — | — | EP | disclosed |
| US-20100152182-A1 | 2,4- Di(hetero)-arylamino-pyrimidine Derivatives as ZAP-70 and/or SYK inhibitors | NOVARTIS AG (CH) | 2010-06-17 | — | — | US | disclosed |
| US-7671063-B2 | 2,4 Di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or syk inhibitors | NOVARTIS AG (CH) | 2010-03-02 | — | — | US | disclosed |
| US-20060247262-A1 | 2,4 Di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or syk inhibitors | NOVARTIS AG (CH) | 2006-11-02 | — | — | US | disclosed |
| EP-1664035-A1 | 2,4 DI (HETERO) -ARYLAMINO-PYRIMIDINE DERIVATIVES AS ZAP-70 AND/OR SYK INHIBITORS | Novartis AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026158-A1 | 2,4 DI (HETERO) -ARYLAMINO-PYRIMIDINE DERIVATIVES AS ZAP-70 AND/OR SYK INHIBITORS | NOVARTIS AG (CH) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152182-A1 | 2,4- Di(hetero)-arylamino-pyrimidine Derivatives as ZAP-70 and/or SYK inhibitors | ZAP70, SYK, BTK | AOC3 3528/4885ACHE 3258/4885SMN1; SMN2 4054/4885 |
| US-20060247262-A1 | 2,4 Di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or syk inhibitors | ZAP70, SYK, BTK | AOC3 3609/4885ACHE 3481/4885SMN1; SMN2 4029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.